Full history for every metric is available with a Kvantra account
Universal Ibogaine Inc. (IBO.V)
Key financial summary
Financials in CAD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
| Operating profit | CAD m | 1 | - | |||||
| Net profit | CAD m | -0 | -0 | -4 | -10 | -2 | -2 | -1 |
| EPS reported | CAD | -0.01 | -0.00 | |||||
| Operating cashflow per share | CAD | -0.00 | -0.00 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.00 | -0.00 | |||||
| Free cash flow | CAD m | -1 | -1 | |||||
| Net debt | CAD m | 2 | 2 | |||||
| Book value equity | CAD m | 1 | 0 | |||||
| Book value per share | CAD | 0.00 | 0.00 | |||||
| Number of shares | m | 232.5 | 308.61 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.52 | 5.75 | |||||
| P/S LTM | x | 1.50 | 0.76 | |||||
| P/FCF LTM | x | -3.80 | -2.36 | |||||
| EV/EBITDA LTM | x | -3.75 | -10.63 | |||||
| EV/Sales LTM | x | 2.48 | 1.92 | |||||
| Earnings Yield LTM | % | -58.83% | -176.48% | |||||
| FCF Yield | % | -26.30% | -42.42% | |||||
| Quality | ||||||||
| ROE | % | -207.00% | -149.60% | |||||
| ROIC | % | 15.14% | 15.14% | |||||
| Operating margin | % | 23.67% | 23.67% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -39.35% | -39.35% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +126.32% | -11.68% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.35 | -0.26 | |||||
| Net Debt/EBITDA | x | -1.48 | -1.48 | |||||
| EBIT/Net interest | x | 3.27 | 3.27 | |||||
| Net debt/market cap | % | 63.21% | 152.31% | |||||
| Net debt/Equity | x | 2.22 | 8.75 | |||||
| Gross debt/equity | x | 2.68 | 9.45 | |||||
Company overview
Universal Ibogaine Inc. is a life sciences enterprise that focuses on creating, obtaining, and managing addiction treatment centers throughout Canada. The company is also actively involved in scheduled clinical trials, researching the efficacy of ibogaine as a treatment for addiction. Its operations are directed from its head office in Calgary, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Universal Ibogaine Inc. (IBO.V)
Universal Ibogaine Inc. is a life sciences enterprise that focuses on creating, obtaining, and managing addiction treatment centers throughout Canada. The company is also actively involved in scheduled clinical trials, researching the efficacy of ibogaine as a treatment for addiction. Its operations are directed from its head office in Calgary, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free